Skip to content
lifestyle.ribbon.co
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Atsena Therapeutics
Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
October 7, 2026
Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
September 30, 2026
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
August 19, 2026
Atsena Therapeutics Receives Orphan Designation from the European Medicines Agency (EMA) for ATSN-101 and ATSN-201
July 23, 2026
Atsena Presents Positive Clinical Data from Its XLRS and LCA1 Gene Therapy Programs at ARVO 2026
May 23, 2026
Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
May 22, 2026
Atsena Therapeutics Announces Upcoming Presentations at Scientific and Medical Meetings
May 20, 2026
Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
April 20, 2026